Suscríbete al boletín semanal

Suscríbete para recibir cada semana el boletín SINC con los contenidos más relevantes y no te pierdas nada de la actualidad científica.

Suscríbete al boletín semanal
If you are registered

You will not be able to connect if you exceed ten failed attempts.

If you are not yet registered

The SINC Agency offers different services depending on your profile.

Select yours:

Journalists Institutions
If you are registered

You will not be able to connect if you exceed ten failed attempts.

If you are not yet registered

The SINC Agency offers different services depending on your profile.

Select yours:

Journalists Institutions
ANALYSIS
History repeats itself with the price of remdesivir
3 July 2020 12:30
Vanessa López

The pharmaceutical company Gilead has announced that the price of their antiviral, used with modest results to treat COVID-19, will be 2083 Euros per patient when the minimum cost of production is 0.83 Euros per dose. The price of medicines should be related to the cost of development and production, plus a fair and reasonable profit, particularly in light of the public effort that has been invested in the R&D chain.